Control-IQ+ Algorithm Refinements
Type 1 & Type 2 Diabetes
CommercialOngoing Development
Key Facts
About Tandem Diabetes
Tandem Diabetes Care has established itself as a formidable innovator in the diabetes technology sector by pioneering a 'software-first' approach to insulin pump design. Its core strategy revolves around its interoperable t:slim X2 and Tandem Mobi hardware platforms, enhanced by the predictive Control-IQ+ algorithm, creating a sticky ecosystem for users. The company's mission is to leverage smart technology and deep user empathy to create new possibilities and improve the lives of people with diabetes, their loved ones, and healthcare providers.
View full company profileTherapeutic Areas
Other Type 1 & Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| GPX-002 | Genprex | Preclinical |
| iOS Compatibility for Mobi | Tandem Diabetes | Development |
| Omnipod 5 International Rollout | Insulet | Commercial |
| Afrezza® | MannKind Corp | Approved |